# Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler

> **NCT04027439** · PHASE2 · COMPLETED · sponsor: **Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA** · enrollment: 37 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Part A: RPL554
- **DRUG:** Part B: RPL554
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04027439
- **Lead sponsor:** Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-10
- **Primary completion:** 2019-05-23
- **Final completion:** 2019-05-23
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04027439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04027439, "Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04027439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*